Cantor Fitzgerald Decreases Earnings Estimates for Omeros

Omeros Co. (NASDAQ:OMER) – Investment analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for shares of Omeros in a note issued to investors on Wednesday, April 2nd. Cantor Fitzgerald analyst O. Brayer now expects that the biopharmaceutical company will earn ($2.19) per share for the year, down from their prior estimate of ($1.73). The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. Cantor Fitzgerald also issued estimates for Omeros’ FY2025 earnings at ($2.19) EPS.

Other equities analysts have also issued reports about the company. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Tuesday, April 1st. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Tuesday, April 1st. Finally, D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, April 1st. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $22.50.

Omeros Price Performance

Shares of OMER opened at $7.06 on Friday. Omeros has a one year low of $2.97 and a one year high of $13.60. The company’s fifty day moving average price is $8.56 and its 200 day moving average price is $7.65. The company has a market capitalization of $409.93 million, a PE ratio of -3.06 and a beta of 2.35.

Omeros (NASDAQ:OMER) last released its quarterly earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter in the prior year, the business posted ($0.15) earnings per share.

Institutional Trading of Omeros

Several institutional investors have recently modified their holdings of OMER. Truvestments Capital LLC lifted its position in Omeros by 116.5% in the fourth quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Omeros by 79.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Omeros during the 4th quarter worth about $46,000. BNP Paribas Financial Markets boosted its position in shares of Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management increased its stake in Omeros by 692.5% in the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 4,404 shares during the period. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.